title: Cardiac and cardiovascular consequences after haematopoietic stem cell transplantation.
abstract: Haematopoietic stem cell transplantation (HCT) is the treatment of choice for defined malignant and non-malignant haematological disorders. The main drawbacks of HCT are early transplant-related mortality and late complications, which interfere with patient outcome, health status and quality of life. In comparison with other post-transplant complications, cardiac or cardiovascular consequences seem to occur at a much lower frequency. Early complications are usually associated with patient history before transplantation, primary diagnosis, age of the patient and associated comorbidities, and the type of transplantation and conditioning used. Late cardiac and cardiovascular events may occur years and even decades after HCT, and are related to cardiotoxic chemotherapy, mediastinal radiation therapy, gender, age at transplantation, cardiovascular risk factors and graft-versus-host disease in allogeneic HCT. As has been observed in long-term survivors of Hodgkin lymphoma, where the incidence of cardiovascular complications emerged as a significant problem with increasing follow-up, it is anticipated that the incidence of these complications after HCT will also increase significantly with increasing follow-up of the survivors. This review presents the available data on early and late cardiac and cardiovascular consequences after HCT, and presents recommendations for cardiac assessment and management of these complications.
authors.affiliation: Division of Haematology, University Hospital, Basel, Switzerland. tichelli@datacomm.ch
authors.forename: André
authors.initials: A
authors.lastname: Tichelli
authors.forename: Smita
authors.initials: S
authors.lastname: Bhatia
authors.forename: Gérard
authors.initials: G
authors.lastname: Socié
mesh_terms: D000367:Age Factors; D000686:Amyloidosis / Q000209:etiology; D018943:Anthracyclines / Q000009:adverse effects; D002318:Cardiovascular Diseases / Q000209:etiology* / Q000517:prevention & control; D006086:Graft vs Host Disease / Q000209:etiology; D006331:Heart Diseases / Q000209:etiology / Q000517:prevention & control; D019650:Hematopoietic Stem Cell Mobilization / Q000009:adverse effects; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D011878:Radiotherapy / Q000009:adverse effects; D012307:Risk Factors; D017741:Survivors
chemical_list: D018943:Anthracyclines